Maxcyte (MXCT) EBITDA Margin (2020 - 2026)

Maxcyte (MXCT) has reported EBITDA Margin for 7 consecutive years, with 127.51% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 2693.0% year-over-year to 127.51% in Q2 2026; TTM through Jun 2026 was 121.38%, a 1617.0% increase from a year earlier, with the FY2025 full-year figure at 144.16%, down 2279.0% from the prior year.
• EBITDA Margin was 127.51% for Q2 2026 at Maxcyte, down from 53.41% in the prior quarter.
• Over five years, EBITDA Margin peaked at 35.89% in Q1 2022 and troughed at 191.71% in Q3 2025.
• A 5-year average of 114.45% and a median of 117.87% in 2026 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin soared 6223 bps in 2022 and plunged 11777 bps in 2023, its largest moves.
• Over 5 years, EBITDA Margin stood at 54.34% in 2022, then grew by 5 bps to 51.68% in 2023, then slumped by 164 bps to 136.25% in 2024, then declined by 2 bps to 139.33% in 2025, then gained by 8 bps to 127.51% in 2026.
• The last three EBITDA Margin figures came in at 127.51% (Q2 2026), 53.41% (Q1 2026), and 139.33% (Q4 2025), per Business Quant data.